Novel strategies for the treatment of lung cancer: Modulation of eicosanoids

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 825-827

  Backlund, Michael G ^a   Amann, Joseph M ^a   Johnson, David H ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ARACHIDONIC ACID; BIOLOGICAL MARKER; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; ERLOTINIB; GLITAZONE DERIVATIVE; ICOSANOID; LEUKOTRIENE; PIOGLITAZONE; PLACEBO; PLATINUM COMPLEX; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; ROSIGLITAZONE; THROMBOXANE; ZILEUTON; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DRUG DERIVATIVE; HYDROXYUREA; LIPOXYGENASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG MEGADOSE; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; NOTE; RANDOMIZED CONTROLLED TRIAL; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EICOSANOIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; LUNG NEOPLASMS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 39749101912     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.9583     Document Type: Editorial

References (27)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
3. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
4. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001
5. Sun S, Schiller JH, Spinola M, et al: New molecularly targeted therapies for lung cancer. J Clin Invest 117:2740-2750, 2007
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
7. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
8. Brown JR, DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10:4266s-4269s, 2004
9. Krysan K, Reckamp KL, Sharma S, et al: The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6:209-220, 2006
10. Wang D, Dubois RN: Prostaglandins and cancer. Gut 55:115-122, 2006
11. Edelman MJ, Watson D, Wang X, et al: Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B trial 30203. J Clin Oncol 26:848-855, 2008
12. Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 357:1841-1854, 2007
13. Khuri FR, Wu H, Lee JJ, et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861-867, 2001
14. Chan AT, Ogino S, Fuchs CS: Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. N Engl J Med 356:2131-2142, 2007
15. Markowitz SD: Aspirin and Colon Cancer: Targeting Prevention? N Engl J Med 356:2195-2198, 2007
16. Murphey LJ, Williams MK, Sanchez SC, et al: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: Determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 334:266-275, 2004
17. Csiki I, Morrow JD, Sandler A, et al: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin Cancer Res 11:6634-6640, 2005
18. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764, 1998
19. Wolff H, Saukkonen K, Anttila S, et al: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997-5001, 1998
20. Yoshimatsu K, Altorki NK, Golijanin D, et al: Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7:2669-2674, 2001
21. Ding Y, Tong M, Liu S, et al: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26:65-72, 2005
22. Yang L, Amann JM, Kikuchi T, et al: Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 67:5587-5593, 2007
23. Fulton AM, Ma X, Kundu N: Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 66:9794-9797, 2006
24. Yang L, Huang Y, Porta R, et al: Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 66:9665-9672, 2006
25. Mann JR, Backlund MG, Buchanan FG, et al: Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 66:6649-6656, 2006
26. Govindarajan R, Ratnasinghe L, Simmons DL, et al: Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481, 2007
27. Hazra S, Batra RK, Tai HH, et al: Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 71:1715-1720, 2007